Interestingly, patients with diabetes and associated chronic renal insufficiency are less able to clear incretin hormone metabolites including GLP-1 9–36 amide [39], which may also provide an area for therapeutic exploitation. This evidence concerns the gene GLP1R and chronic kidney disease.